



## NEWS RELEASE

### AUSTRALIS CAPITAL INVESTS IN FOLIUM BIOSCIENCES A GLOBAL LEADER IN NON-PSYCHOACTIVE CANNABINOID PRODUCTION

**LAS VEGAS, NV, January 15, 2019** – Australis Capital Inc. (CSE: AUSA) (“**Australis**” or the “**Company**”) is pleased to announce the Company has invested \$3,000,000 USD in Folium Biosciences (“**Folium**”), the largest vertically integrated producer, manufacturer, and distributor of hemp derived phytocannabinoids in the United States. Folium also owns and operates the largest phytocannabinoid extraction and purification facility in the United States, with plans for a new pharmaceutical division and the completion of their Canadian facility in 2019.

“With the passing of the 2018 Farm Bill and the floodgates opening for this vibrant and exciting industry, we are poised for strong growth this year,” said Kashif Shan, CEO of Folium. “As a global industry leader and authority in PCR hemp oil extraction and product development, we welcome Australis’ participation in this private placement as we continue to pave the way and dominate the marketplace.”

Supplying the market with its own unique 0.0% THC phytocannabinoid-rich hemp oil, Folium is a global leader in non-psychoactive cannabinoids. Folium’s chromatographic purification process selectively removes the psychoactive component from the phytocannabinoid-rich hemp oil. Folium is certified by the Colorado Department of Public Health and Environment as a producer of 0.0% THC products, including CBD hemp oil, CBD gel caps, water soluble CBD, Cannabidiol HYDROPCR, CBD e-liquid, CBD concentrates, CBD for pets, CBD salves and balms, CBD tinctures, CBD face masks, and white-label CBD products.

“Our strategic investment in Folium Biosciences provides Australis and our brands access to the leading player in the fast-evolving United States CBD market,” said Scott Dowty, CEO of Australis. “Folium’s breadth of expertise, spanning production, extraction, branding and commercialization, will greatly benefit Australis as we introduce and expand our CBD product offerings in the United States in the months and years ahead.”

#### **About Australis Capital Inc.**

Australis Capital identifies and invests in the cannabis industry predominately in the United States, a highly regulated, fragmented, rapidly expanding and evolving industry. Investments may include and are not limited to equity, debt or other securities of both public and private companies, financings in exchange for royalties or other distribution streams, and control stake acquisitions. Australis Capital adheres to stringent investment criteria and will focus on significant near and mid-term high-quality opportunities with strong return potentials while maintaining a steadfast commitment to governance and community. Australis Capital’s Board members and Management have material experience with, and knowledge of, the cannabis space in the U.S., extensive backgrounds in highly regulated industries, adherence to stringent regulatory compliance, public company and operational expertise. In addition to the Company’s expertise and strong execution on strategic M&A, which to date includes Rthm Technologies Inc., Body and

Mind Inc. and Quality Green Inc., Australis has developed strategic partnerships with companies such as Wagner Dimas.

Australis' Common shares trade on the CSE under the symbol "AUSA".

For further information about Australis, please visit the website at [ausacap.com](http://ausacap.com) or contact the Company by e-mail at [ir@ausacap.com](mailto:ir@ausacap.com).

ON BEHALF OF THE BOARD OF DIRECTORS

*"Scott Dowty"*

---

Scott Dowty  
Chief Executive Officer

**Contact:**  
Michael J. Carlotti  
Chief Financial Officer  
[IR@ausacap.com](mailto:IR@ausacap.com)

### **Forward-Looking Information Statement**

*This news release contains statements and information that, to the extent that they are not historical fact, constitute "forward-looking information" within the meaning of applicable securities legislation, including statements in respect of future CBD product offerings. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.*

*Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company's management to predict all of such factors and to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.*

*The CSE has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Regulation Services*

*Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.*

###